drugset / Trial / NCT05154630
Study on Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignant Tumors
NaSingle-groupOpen-labelTreatment
Summary
This study is divided into two phases: dose escalation and cohort expansion. The dose escalation stage aims to evaluate the tolerability, pharmacokinetic characteristics and safety of TQB2858 injection in subjects with advanced malignant tumors. The cohort expansion phase aims to evaluate the initial efficacy and safety of TQB2858 injection in patients with soft tissue sarcoma, and to explore treatment-related biomarkers.
Timeline
- Start
- 2022-01-14
- Primary completion
- 2023-03-31
- Completion
- 2023-06-30
Outcome
Outcome not reported
Stopped: “The sponsor has decided to terminate this study based on the current clinical research status of dual antibody drugs and full communication with the investigators.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TQB2858 | Protein / enzyme biologic | 3 mg | Intravenous |
| Subject | TQB2858 | Protein / enzyme biologic | 60 mg | Intravenous |
| Subject | TQB2858 | Protein / enzyme biologic | 600 mg | Intravenous |
| Subject | TQB2858 | Protein / enzyme biologic | 1200 mg | Intravenous |
| Subject | TQB2858 | Protein / enzyme biologic | 1800 mg | Intravenous |